May 17, 2026 by Geoffrey SeilerThe AI Stock With a 10-Year Head Start That Wall Street Still Hasn't Fully Priced InAlphabet has a huge advantage with its TPUs, which it developed more than a decade ago.
May 17, 2026 by Matt DiLalloAres Capital's 10% Yield Just Survived a Tough Quarter. Is the BDC Still a Buy?Ares Capital isn't worried about last quarter's challenges.
May 17, 2026 by Adam LevyMicron's and Sandisk's Futures Are Heavily Influenced by 2 Foreign Chip Companies. Here's How to Buy Them.These memory chipmakers have major expansion plans underway.
May 17, 2026 by Seena HassounaA China Tech Fund Opens a Biotech Position — Here's What That Actually SignalsLegend Biotech develops cell therapies for cancer, with a pipeline spanning hematologic malignancies and solid tumors.
May 17, 2026 by Beth McKennaNvidia Stock Is Poised to Rocket From the Booming Space EconomyNvidia dominates artificial intelligence (AI) on Earth – and it should do the same for AI in space.
May 17, 2026 by Seena HassounaWith YMM Down 29%, First Beijing Bought 13 Million More SharesFull Truck Alliance is a top digital freight platform in China, connecting shippers and truckers through tech-enabled logistics services.
May 17, 2026 by Seena HassounaGDS Was Already Up 47% — Pinpoint Tripled Its Stake AnywayGDS Holdings develops and operates data centers in China, serving major cloud, internet, and financial sector clients.
May 17, 2026 by Geoffrey SeilerThe AI Stock With a 10-Year Head Start That Wall Street Still Hasn't Fully Priced InAlphabet has a huge advantage with its TPUs, which it developed more than a decade ago.
May 17, 2026 by Keith NoonanWhy Plug Power Stock Skyrocketed This WeekPlug Power served up some promising news for investors this week.
May 17, 2026 by Marc GubertiSnapchat: Don't Rush to Buy This Social Media StockSnap is unprofitable after almost 15 years and doesn't have the revenue growth rates of an exciting start-up.
May 17, 2026 by Kailey Hagen, CFPThink Delaying Social Security Is Risky? The Truth About Timing Your Benefits.There's no cut-and-dried answer about the best time to sign up for benefits.
May 17, 2026 by Seena HassounaM&G Shaved 2.4% of Methanex After a Near-DoublingMethanex supplies methanol worldwide, using integrated operations and its own fleet to serve industrial clients across major global markets.
May 17, 2026 by Jonathan PoncianoMaze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in SharesMaze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metabolic diseases.
May 17, 2026 by Jonathan PoncianoTyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More SharesTyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline.
May 17, 2026 by Jonathan PoncianoThis Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 MillionViridian Therapeutics develops monoclonal antibody therapies targeting serious diseases, with a primary focus on thyroid eye disease.
May 17, 2026 by Micah ZimmermanWhere Could Palantir Be in 10 Years? The Bull and Bear Cases.Palantir remains a high-variance AI infrastructure bet where narrative and execution will matter equally over the next decade.
May 17, 2026 by Keith NoonanWhy Poet Technologies Stock Skyrocketed This WeekPoet's new contract announcement powered huge gains for the stock.
May 17, 2026 by Jonathan PoncianoThis Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 MillionThis clinical-stage biotech develops oral therapeutics for chronic diseases, with a pipeline centered on metabolic and pulmonary targets.
May 17, 2026 by Matt DiLalloAres Capital's 10% Yield Just Survived a Tough Quarter. Is the BDC Still a Buy?Ares Capital isn't worried about last quarter's challenges.
May 17, 2026 by Jonathan PoncianoAlumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last QuarterAlumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.
May 17, 2026 by Jonathan PoncianoWhy This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock RallyThis clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions.
May 17, 2026 by Ben GranWhy Would Anyone Buy SPYM Instead of QQQ?Buying the S&P 500 instead of the Qs could help you avoid relying too heavily on tech stocks.
May 17, 2026 by Jonathan PoncianoErasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million MoreThis clinical-stage biotech targets RAS/MAPK pathway cancers with a pipeline of novel small molecule oncology therapies.
